Novo will make an authorized generic version of its best-selling insulin, Novolog, available to patients in January 2020 at a 50 percent discount.
The list price for one vial will be $144.68.
Novo also created a cash card program that can be used by patients to buy three vials or two packs of pens of Novo’s analog insulins at a flat rate of $99 per month. According to Novo, that is an adequate supply for one month.
Novo’s decision to offer cheaper alternatives follows similar moves by big insulin makers, Sanofi and Eli Lilly.
In April, Sanofi said it would cut the cost of its insulin products to $99 per month. In May, Eli Lilly started selling a half-priced version of its Humalog insulin.
More articles on pharmacy:
Civica Rx says it isn’t afraid of competition
Cigna rolls out plan to fully cover expensive gene therapies
Rutgers to close 3 on-campus pharmacies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.